Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)

Inclusion Criteria:

* Joined the study voluntarily and signed informed consent form
* Eastern Cooperative Oncology Group performance status of 0 to 1
* Life expectancy of more than 5 years
* Colorectal adenocarcinoma / mucinous adenocarcinoma / signet ring cell cancer confirmed by histopathology
* Stage T4NanyM0 cancer; or stage T3NanyM0 mucinous adenocarcinoma / signet ring cell cancer / adenocarcinoma with partly mucinous adenocarcinoma or signet ring cell cancer
* R0 resection of colorectal cancer
* Neutrophils (ANC) ≥ 1.5×10\^9/L, Platelet count (Pt) ≥ 100× 10\^9/L, Hemoglobin (Hb) ≥ 80 g/L, Hepatic function: ALT and AST ≤ 2.5 times upper limit of normal (ULN) and TBIL ≤ 1.5 times ULN, Renal function: creatinine ≤ 1.5 times ULN
* Use of an effective contraceptive for adults to prevent pregnancy

Exclusion Criteria:

* Rectal cancer below peritoneal reflection (≤ 8cm above the anal verge)
* Other malignant tumors within the past 5 years, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived from radical treatment
* Severe adhesion of peritoneal cavity impossible to separate
* Abdominal infection
* Allergic to raltitrexed, 5-FU, and oxaliplatin; Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
* Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior
* Drug addiction, Alcoholism or AIDS
* Impossible to tolerate the operation due to severe cardiac, lung, and vascular diseases
* Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives